�The European Medicines Agency (EMEA) has been formally notified by
Celgene Europe Ltd of Pharmion Ltd's decision to withdraw the
application for a centralised marketing empowerment for the medicine
Orplatna (satraplatin) 10 mg and 50 mg capsules. Orplatna was expected
to be used, in combination with prednisone and prednisolone, in the
intervention of patients with metastatic hormone-refractory prostate gland cancer
